Transcept's NDA Intermission For Insomnia Drug Intermezzo Set To End In First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from a driving impairment study strengthen the case for approval, the company says.
You may also be interested in...
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
Second Intermezzo "Complete Response" Threatens Transcept's Partnership Payments
If approval is not gained by Sept. 23, partner Purdue Pharma will not have to make a $30 million milestone payment.